CNS Indications
The CNS drug pipeline organized by condition — 57 psychiatric and neurological indications, MeSH/ICD-11 coded, each with the compounds in development and trials recruiting.45 indications with tracked programs · 135 compounds across the pipeline · 97 upcoming readouts.
Neurocognitive Disorders (11)
- Alzheimer's disease16 compounds1 Phase 3++8 in subtypes1,537 trials3 subtypes
- Parkinson's disease7 compounds3 Phase 3+1,331 trials2 subtypes
- Agitation in Alzheimer's disease5 compounds2 Phase 3+16 trials
- Alzheimer's disease psychosis3 compounds2 Phase 3+9 trials
- Huntington's disease2 compounds141 trials
- Frontotemporal dementia1 compound63 trials
- Lewy body dementia1 compound+1 in subtypes65 trials1 subtype
- Lewy body dementia psychosis1 compound2 trials
- Postoperative delirium1 compound1 trial
- Dominantly inherited Alzheimer's diseaseno programs yet
- Parkinson's disease psychosis19 trials
Mood Disorders (6)
- Major depressive disorder41 compounds9 Phase 3++12 in subtypes1,650 trials2 subtypes
- Treatment-resistant depression9 compounds1 Phase 3+156 trials
- Bipolar depression6 compounds2 Phase 3+339 trials
- Bipolar disorder5 compounds2 Phase 3++6 in subtypes778 trials1 subtype
- Postpartum depression3 compounds1 Phase 3+77 trials
- Intermittent explosive disorderno programs yet
Neurological Disorders (6)
- Amyotrophic lateral sclerosis3 compounds2 Phase 3+429 trials
- Epilepsy3 compounds2 Phase 3+880 trials
- Migraine2 compounds823 trials
- Multiple sclerosis2 compounds2 Phase 3+1,154 trials
- Neuropathic pain2 compounds1 Phase 3+629 trials
- Tourette syndrome2 compounds1 Phase 3+78 trials
Substance Use Disorders (6)
- Alcohol use disorder1 compound369 trials
- Cannabis use disorder1 compound109 trials
- Cocaine use disorder1 compound97 trials
- Opioid use disorder1 compound368 trials
- Tobacco use disorder1 compound492 trials
- Stimulant use disorder+1 in subtypes21 trials1 subtype
Anxiety & Trauma Disorders (5)
- Generalized anxiety disorder6 compounds1 Phase 3+185 trials
- Post-traumatic stress disorder6 compounds3 Phase 3+482 trials
- Social anxiety disorder5 compounds2 Phase 3+96 trials
- Obsessive-compulsive disorder2 compounds176 trials
- Panic disorder69 trials
Neurodevelopmental Disorders (5)
- Attention-deficit/hyperactivity disorder4 compounds2 Phase 3+652 trials
- Autism spectrum disorder2 compounds1 Phase 3+420 trials
- Fragile X syndrome2 compounds1 Phase 3+73 trials
- Down Syndrome1 compound2 trials
- Rett syndrome46 trials
Sleep-Wake Disorders (4)
- Narcolepsy5 compounds3 Phase 3+12 trials
- Idiopathic Hypersomnia2 compounds1 Phase 3+2 trials
- Insomnia2 compounds2 Phase 3+427 trials
- Excessive daytime sleepiness1 compound1 Phase 3+57 trials
Psychotic Disorders (3)
- Schizophrenia24 compounds11 Phase 3+1,711 trials1 subtype
- First-episode psychosisno programs yet
- Schizoaffective disorder326 trials
Cerebrovascular & Acute Brain Injury (2)
- Intracerebral hemorrhage1 compound4 trials
- Neurobehavioral disinhibition after traumatic brain injuryno programs yet
Eating Disorders (2)
- Anorexia nervosa1 compound63 trials
- Binge eating disorder1 compound1 Phase 3+62 trials
Movement Disorders (2)
- Tardive Dyskinesia1 compound1 trial
- Levodopa-induced dyskinesia in Parkinson's diseaseno programs yet
Pain (2)
- Fibromyalgia2 compounds2 Phase 3+4 trials
- Inherited erythromelalgiano programs yet
Neurodegenerative Disorders (1)
- Multiple System Atrophy1 compound1 trial
Suicide & Self-Harm (1)
- Suicidal ideation81 trials
Trauma and Stressor-Related Disorders (1)
- Acute Stress Disorder2 compounds2 trials